RJA
AGIO icon

Raymond James & Associates’s Agios Pharmaceuticals AGIO Stock Holding History

Raymond James & Associates’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,350
Closed -$375K – 3876
2022
Q4 		$375K Sell
13,350
-2,199
-14% -$62K ﹤0.01% 3078
2022
Q3 		$440K Buy
+15,549
New +$417K ﹤0.01% 2946

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Raymond James & Associates's AGIO Position: Q1 2023 in Review

Raymond James & Associates sold out of Agios Pharmaceuticals (AGIO) in Q1 2023, closing a stake of 13,350 shares — an estimated $375K sold.

Raymond James & Associates first reported a position in AGIO in Q3 2022 and held it in 2 quarters. The position peaked at $440K in Q3 2022. 163 funds tracked by Wall St. Rank hold AGIO as of Q1 2023.

  • Raymond James & Associates reported no remaining Agios Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 13,350 Agios Pharmaceuticals shares in Q1 2023, an estimated $375K.
  • Raymond James & Associates first reported a position in Agios Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Raymond James & Associates's Agios Pharmaceuticals position peaked at $440K in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.